Original ArticleNeurological adverse effects of cancer chemotherapyThomas, Adam C.G.Author Information Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium Correspondence to Adam C.G. Thomas, MPharm, MRPharmS, IPresc, Dudley Group NHS Foundation Trust, Dudley, West Midlands DY1 2HQ, UK. Tel: +44 13 8424 4311; e-mail: [email protected] Editor: R E Ferner, MSc, MD, FRCP, Director of the West Midlands Centre for Adverse Drug Reaction Reporting and Consultant Physician at City Hospital, Birmingham, UK. Assistant Editor: Mr C Anton, MA, MEng. Editorial Board: Australia: Dr M Kennedy, Professor G M Shenfield, Denmark: Professor J S Schou; England: Dr J K Aronson; Netherlands: Professor C J van Boxtel, Dr B H Ch Stricker; New Zealand: Dr T Maling; Scotland: Dr D N Bateman; Wales: Professor P A Routledge. Adverse Drug Reaction Bulletin: February 2013 - Volume 278 - Issue 1 - p 1071-1074 doi: 10.1097/FAD.0b013e32835ed7b5 Buy Metrics Abstract Summary Neurological adverse events can be broadly divided into those affecting the central nervous system and those affecting the peripheral nervous system. Chemotherapy-induced neurological adverse effects can reduce treatment efficacy or lead to treatment failure, and can impair the patient's quality of life. Neurotoxicity is more likely when chemotherapy is combined with radiotherapy. Concomitantly prescribed supportive therapy, and the disease itself, can make it difficult to identify the cause of neurological adverse effects. However, the type and degree of toxicity has been shown to be related to the drug type, dose-intensity and cumulative dosage. Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.